Diplomat Pharmacy (DPLO) Tops Q2 EPS by 10c, Beats on Revenues; Boosts FY17 EPS, Reduces FY17 Top-End of Revenue Range Guide

Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.25, $0.10 better than the analyst estimate of $0.15. Revenue for the quarter came in at $1.13 billion versus the consensus estimate of $1.14 billion.

2017 Financial Outlook

For the full-year 2017, we are updating our previous financial guidance:

• Revenue between $4.3 and $4.6 billion, versus the previous range of $4.3 and $4.7 billion
• Net income attributable to Diplomat between $10 and $16 million, versus the previous range of $6.5 and $15.5 million
• Adjusted EBITDA between $97 and $103 million, versus the previous range of $95 and $103 million
• Diluted EPS between $0.15 and $0.23, versus the previous range of $0.09 and $0.23
• Adjusted EPS between $0.71 and $0.79, versus the previous range of $0.54 and $0.70

Our EPS and Adjusted EPS expectations assume approximately 68,600,000 weighted average common shares outstanding on a diluted basis and a tax rate of 26%, versus the previous tax rate of 35% and 40% for the high and low of the range respectively, for the full year 2017, which could differ materially.

GUIDANCE:

Diplomat Pharmacy sees FY2017 EPS of $0.71-$0.79, versus the consensus of $0.65. Diplomat Pharmacy sees FY2017 revenue of $4.3-4.6 billion, versus the consensus of $4.57 billion.

Second Quarter 2017 Highlights include:

• Revenue of $1,126 million, compared to $1,089 million, an increase of 3.5%
• Total prescriptions dispensed of 220,000, compared to 241,000
• Gross margin of 7.5% versus 7.6%
• Gross profit per prescription dispensed of $371, compared to $339
• Net income attributable to Diplomat of $3.6 million, compared to $8.5 million
• Adjusted EBITDA of $25.2 million, compared to $29.6 million
• Adjusted EBITDA margin of 2.2% versus 2.7%
• EPS of $0.05 per diluted common share versus $0.13
• Adjusted EPS of $0.25 versus $0.23

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c